Product NDC: | 0591-3817 |
Proprietary Name: | ipratropium bromide and albuterol sulfate |
Non Proprietary Name: | ipratropium bromide and albuterol sulfate |
Active Ingredient(s): | 2.5; .5 mg/3mL; mg/3mL & nbsp; ipratropium bromide and albuterol sulfate |
Administration Route(s): | RESPIRATORY (INHALATION) |
Dosage Form(s): | SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0591-3817 |
Labeler Name: | Watson Laboratories, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA202496 |
Marketing Category: | ANDA |
Start Marketing Date: | 20130513 |
Package NDC: | 0591-3817-60 |
Package Description: | 12 POUCH in 1 CARTON (0591-3817-60) > 5 VIAL in 1 POUCH > 3 mL in 1 VIAL |
NDC Code | 0591-3817-60 |
Proprietary Name | ipratropium bromide and albuterol sulfate |
Package Description | 12 POUCH in 1 CARTON (0591-3817-60) > 5 VIAL in 1 POUCH > 3 mL in 1 VIAL |
Product NDC | 0591-3817 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | ipratropium bromide and albuterol sulfate |
Dosage Form Name | SOLUTION |
Route Name | RESPIRATORY (INHALATION) |
Start Marketing Date | 20130513 |
Marketing Category Name | ANDA |
Labeler Name | Watson Laboratories, Inc. |
Substance Name | ALBUTEROL SULFATE; IPRATROPIUM BROMIDE |
Strength Number | 2.5; .5 |
Strength Unit | mg/3mL; mg/3mL |
Pharmaceutical Classes | Anticholinergic [EPC],Cholinergic Antagonists [MoA],Adrenergic beta2-Agonists [MoA],beta2-Adrenergic Agonist [EPC] |